Copyright © 2019. Inderes Oy. All rights reserved.
Faron Pharmaceuticals
1503 investors follow this company
The company is not covered. See all listed companies from here.
BUY 4.67 LOWEST 4.53 VOLUME 5 214
SELL 4.70 HIGHEST 4.70 VALUE 0,024 Milj. EUR

Would you like to see our recommendations and target prices?

You already have an Inderes account? Log in from here.

Analyst

Tulevat tapahtumat

24
Sep
Osavuosikatsaukset

Latest insider trading

Net impact profile

Stock release
27.7.
2020

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Company announcement, 27 July 2020 at 9.00 AM (EET)

TURKU - FINLAND, 27 July 2020 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, is pleased to announce that Cairn Financial Advisers LLP has been appointed as Nominated Adviser to the Company with immediate effect.  Panmure Gordon (UK) Limited continues to act as the Company's Broker.

For further information, please contact:

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

Stock release
8.7.
2020

("Faron" or the "Company")

Company announcement, 8 July 2020 at 5 PM (EEST)

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that Mr Toni Hänninen, Chief Financial Officer of the Company, acquired 4,400 ordinary shares in Faron at a price of €3.510 per share on 8 July 2020. Following these purchases, Mr Hänninen holds 54,697 ordinary shares in the Company.

Stock release
16.6.
2020

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron hosts virtual R&D Day today

Company announcement, 16 June 2020 at 9.01 AM (EET)
 

Stock release
16.6.
2020

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron provides update on pipeline progress ahead of R&D Day

Company announcement, 16 June 2020 at 9.00 AM (EET)

Inside information
 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today provides an update on the progress of its two clinical stage programmes, Clevegen and Traumakine, ahead of the Company's virtual R&D Day.

 

Clevegen

Stock release
15.6.
2020

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron receives €2.1 million funding from Business Finland for Traumakine manufacturing

Company announcement, 15 June 2020 at 9.00 AM (EET)
Insider information

Stock release
11.6.
2020

Faron selected for €2.5 million grant from European Innovation Council Accelerator pilot for MATINS study acceleration

Company announcement, 11 June 2020 at 09.00 AM (EET)

Inside Information

TURKU - FINLAND Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that, it has been selected to receive a €2.5 million grant from the European Innovation Council (EIC) Accelerator pilot scheme to progress the MATINS Study and related business activities.

Stock release
1.6.
2020

Faron Pharmaceuticals Oy

("Faron" or the "Company")
Safety and efficacy results from Part I of MATINS study presented in poster at ASCO20 Virtual
  • Patient recruitment for Part II in multiple cohorts progressing well  

 

Company announcement, 01 June 2020 at 9.00 AM (EET)
Inside information

Stock release
28.5.
2020

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Company announcement, 28 May 2020 at 9.00 AM (EET)

 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces plans to host a virtual R&D Day via webcast on Tuesday, 16 June 2020 at 3pm EEST, 1pm BST, 8am EDT.

Stock release
20.5.
2020

· Detailed analyses following INTEREST trial conclude glucocorticoids block the upregulation of CD73 in the lung capillaries and inhibit interferon signalling

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that the results of its detailed analyses into the effects of glucocorticoids on intravenous (IV) interferon (IFN) beta-1a activity, which arose following the INTEREST trial in 2018, have been published in Intensive Care Medicine, a world leading journal in the field of critical care.

Stock release
13.5.
2020

                  Faron Pharmaceuticals Oy

                   ("Faron" or the "Company")

Exercise of options

Issue of equity

Company announcement, 13 May 2020 at 15.00 (EEST)

Faron Pharmaceuticals

English translation unavailable for Faron Pharmaceuticals.